The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML

References

• Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. In: IARC CancerBase No.5. IARCPress, Lyon, France, (2001).
   Google Scholar
• Ries LAG, Eisner MP, Kosary CL et al SEER Cancer Statistics Revierg 1973–1999. National Cancer Institute, Bethesda, MD, USA, (2002).
   Google Scholar
• National Cancer Institute. NCI Fact Book US Department of Health and Human Services, Public Health Service, National Institutes of Health, WA, USA, (2001).
   Google Scholar
• Miller BA, Kolonel LN, Bernstein L et al Leukemias — US Racial/Ethnic Cancer Patterns. In: Racial/Ethnic Patterns of Cancer in the United States 1988–1992. National Cancer Institute, Bethesda, MD, USA, (1996).
   Google Scholar
• Levi F, Lucchini F, LaVecchia C. Cancer mortality in the European Union, 1988–1997: the fall may approach 80,000 deaths a year. hit. j Cancer98, 636–637 (2002).
   Google Scholar
• Zagonel V, Babare R, Spazzapan S et al. Treatment of multiple myeloma and acute myelogenous leukemia in the elderly: an update. Rays 22 (Suppl. 1), 30–36 (1997).
   Google Scholar
• Zent CS, Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 92(5),1325–1330 (2001).
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Gokbuget N. Recent approaches in acute lymphoblastic leukemia in adults. Grit. Rev Oncol Hematol 36(1), 49–58 (2000).
   Google Scholar
• Thomas X, Olteanu N, Charrin C, Lheritier V, Magaud JP, Fiere D. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am. Hematol 67(2), 73–83 (2001).
   Google Scholar
• Chan KW Acute lymphoblastic leukemia. Curr. Probl Pediatr. Adolesc. Healthcare 32(2), 40–49 (2002).
   Google Scholar
• •Recent review of acute lymphoblastic leukemia (ALL), particularly in childhood.
   Google Scholar
• Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl. J. Med. 341(14), 1051–1062 (1999).
   Google Scholar
• Pui CH, Evans WE. Acute lymphoblastic leukemia. N EngLJ Med. 339 (9), 605–615 (1998).
   Google Scholar
• Andritsos L, Khoury H. Chronic lymphocytic leukemia. Curr Treat. Options Oncol 3(3), 225–231 (2002).
   Google Scholar
• Lowenberg B. Managing therapy in older adult patients with acute myeloid leukemia. Semin. Hematol 38(3 Suppl. 6), 10–16 (2001).
   Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N. Engl. Med 340(17), 1330–1340 (1999).
   Google Scholar
• Kipps TJ. Chronic lymphocytic leukemia and related diseases. In: Williams Hematology Beutler E, Coller BS, Lichtman MA, Kipps TJ, Seligsohn U (Eds). McGraw Hill, NY, USA, 1163–1194 (2001).
   Google Scholar
• Faderl S, Talpaz M, Estrov Z, Kantaijian HM. Chronic myelogenous leukemia: biology and therapy. Ann. Intern Med. 131(3), 207–219 (1999).
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Baer MR, Carabasi MH et al NCCN Practice Guidelines for Acute Myelogenous Leukemia. Oncology ff-Iuntingt)14(11A), 53–61 (2000).
   Google Scholar
• O'Donnell MR, Appelbaum F, Bishop M, Estey EH, Greyer M, Maslak P NCCN Acute Leukemia Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt.)10\(Suppl. 11), 205–221 (1996).
   Google Scholar
• Hamblin TJ. Achieving optimal outcomes in chronic lymphocytic leukaemia. Drugs 61(5), 593–611 (2001).
   Google Scholar
• Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 16(6), 1015–1027 (2002).
   Web of Science ®Google Scholar
• Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 16(6), 985–992 (2002).
   Google Scholar
• Mayer RJ, Davis RB, Schiffer CA et al Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl. J. Med. 331(14), 896–903 (1994).
   Google Scholar
• Buchner T, Hiddemann W, Wormann B et al Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Co-operative Group. B/ooc/93(12), 4116–4124 (1999).
   Google Scholar
• National Cancer Institute. Childhood Acute 11/4eloicl Leukemia/other 11/4eloicl Malignancies a3D(221): Treatment. National Cancer Institute, Bethesda, MD, USA, (2002).
   Google Scholar
• Cassileth PA, Harrington DP, Appelbaum FR et al Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. NEngl.J Med. 339(23), 1649–1656 (1998).
   Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA et al Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Co-operative Oncology Group Study. B/ooc/96(13), 4075–4083 (2000).
   Google Scholar
• Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocyztic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 93(12), 4131–4143 (1999).
   PubMed Web of Science ®Google Scholar
• Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. B/ooc/89(12), 4531–4536 (1997).
   Google Scholar
• Aversa F, Tabilio A, Velardi A et al Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl. I Med. 339 (17), 1186–1193 (1998).
   Google Scholar
• Larson RA, Dodge RK, Burns CP et al A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85(8), 2025-2037 (1995).
   Google Scholar
• Pui CH. Acute lymphoblastic leukemia. Pecliatr Gun. North Am. 44(4), 831–846 (1997).
   Google Scholar
• Uderzo C, Balduzzi A. Allogeneic bone marrow transplantation versus chemotherapy in childhood very high risk acute lymphoblastic leukemia in first complete remission: a controversial issue. Haematologica 87\(Suppl. 8), 47–50 (2002).
   Google Scholar
• Sierra J, Storer B, Hansen JA et al Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching and marrow cell dose. Blood 89(11), 4226–4235 (1997).
   PubMed Web of Science ®Google Scholar
• Pigneux A, Tanguy ML, Michallet M et al. Prior treatment with interferon-a does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Br. Haematol 116 (1), 193–201 (2002).
   Google Scholar
• Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 17 (Suppl. 3), S5—S6 (1996).
   Google Scholar
• National Cancer Institute. Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation. National Cancer Institute, Bethesda, MD, USA, (2002).
   Google Scholar
• Carella AM, Frassoni F, Melo J et al New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. liaematologica 82(4), 478–495 (1997).
   PubMedGoogle Scholar
• Guilhot F, Chastang C, Michallet M et al. Interferon a-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl. Med. 337(4), 223–229 (1997).
   Google Scholar
• Novartis. Gleevec (imatinib mesylate) package insert. Novartis, East Hanover, NJ, USA, (2001).
   Google Scholar
• Binet JL, Auquier A, Dighiero G et al A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer48(1), 198–206 (1981).
   PubMed Web of Science ®Google Scholar
• Hossfeld DK. Chronic lymphocytic leukaemia: risk-adapted therapy. Ann. Oncol 11 (Suppl. 3), 197–198 (2000).
   Google Scholar
• Diehl LF, Kamell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Database report on age, gender, treatment and outcomes of patients with chronic lymphocytic leukemia. Cancer 86(12), 2684–2692 (1999).
   Google Scholar
• Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Co-operative Group on Chronic Lymphocytic Leukemia. N Engl. I Med. 338(21), 1506–1514 (1998).
   Google Scholar
• Toze CL, Shepherd JD, Connors JM et al Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Man ow Transplant. 25(6), 605–612 (2000).
   Google Scholar
• Rai KR. Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment. Thematologica 84,94–95 (1998).
   Google Scholar
• Wyeth-Ayerst Pharmaceuticals. Mylotarg (gemtuzumab ozogamicin) package insert. Wyeth-Ayerst Pharmaceuticals, Philadelphia, PA, USA, (2001).
   Google Scholar
• Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Exp. Opin. Biol. Ther.1 (5), 893–901 (2001).
   Google Scholar
• Berlex Laboratories. Campath® (alemtuzumab) package insert. Berlex Laboratories, Richmond, CA, USA, (2001).
   Google Scholar
• Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin. Oncol 28(5 Suppl. 17), 9–18 (2001).
   Google Scholar
• Druker BJ, Sawyers CL, Kantaijian H et al. Activity of a specific inhibitor of the BCR—ABL tyrosine kinase in the blast crisis of chronic myeloizd leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl. Med 344(14), 1038–1042 (2001).
   Google Scholar
• Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood 99(6), 1928–1937 (2002).
   PubMed Web of Science ®Google Scholar
• Kelly LM, Yu JC, Boulton CL et al CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 1(5), 421–432 (2002).
   Google Scholar
• Weisberg E, Boulton C, Kelly LM et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1(5), 433–443 (2002).
   Google Scholar
• Fenaux P, Le Deley MC, Castaigne S et al Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. B/ooc/82(11), 3241–3249 (1993).
   Google Scholar
• Mandelli F, Diverio D, Avvisati G et al Molecular remission in PMURAR a-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Co-operative Groups. B/ooc/90(3), 1014–1021 (1997).
   Google Scholar
• Cell Therapeutics. Trisenox (arsenic trioxide) package insert. Cell Therapeutics, Seattle, WA, USA, (2001).
   Google Scholar
• Stalfelt AM. Quality of life of patients with acute myeloid leukaemia. Leuk Res. 18(4), 257–267 (1994).
   Google Scholar
• Wolcott DL, Wellisch DK, Fawzy Fl, Landsverk J. Adaptation of adult bone marrow transplant recipient long-term survivors. 7iamplantation 41,478–484 (1986).
   Google Scholar
• Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan KM. Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Tramplant.11 (4), 319–327 (1993).
   PubMed Web of Science ®Google Scholar
• Wingard JR, Curbow B, Baker F, Piantadosi S. Health, functional status and employment of adult survivors of bone marrow transplantation. Ann. Intern. Med. 114(2), 113–118 (1991).
   Google Scholar
• Altmaier EM, Gingrich RD, Fyfe MA. Two-year adjustment of bone marrow transplant survivors. Bone Marrow 7iansplant. 7(4), 311–316 (1991).
   Google Scholar
• Schumacher A, Kessler T, Buchner T, Wewers D, van de Loo J. Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy — a longitudinal study. Leukemia 12(4), 586–592 (1998).
   Google Scholar
• •Comprehensive long-term quality of life study addressing the health-related quality of life impact of chemotherapy in acute myeloid leukemia.
   Google Scholar
• Schumacher A, Wewers D, Heinecke A et al Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia. Leuk. Res. 26(4), 355–362 (2002).
   PubMed Web of Science ®Google Scholar
• Lesko LM, Ostroff JS, Mumma GH, Mashberg DE, Holland JC. Long-term psychological adjustment of acute leukemia survivors: impact of bone marrow transplantation versus conventional chemotherapy. Psychosom. Med. 54(1), 30–47 (1992).
   Google Scholar
• Uyl-de Groot CA, Lowenberg B, Vellenga E, Suciu S, Willemze R, Rutten FE Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. BE J. 1-Lematol 100(4), 629–636 (1998).
   Google Scholar
• Socie G, Mary JY, Esperou H et al Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation. BE J. 1-Lematol. 113(1), 194–201 (2001).
   Google Scholar
• Greenberg DB, Komblith AB, Herndon JE et al Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971–1988: predictors for later psychologic distress. Cancer 80 (10), 1936-1944 (1997) .
   Google Scholar
• Zittoun R, Suciu S, Watson M et al. Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIIVIEMA AML 8A trial. Bone Man ow 7iansplant. 20(4), 307–315 (1997).
   Google Scholar
• Wellisch DK, Centeno J, Guzman J, Belin T, Schiller GJ. Bone marrow transplantation versus high-dose cytorabine-based consolidation chemotherapy for acute myelogenous leukemia. A long-term follow-up study of quality-of-life measures of survivors. Fiychosomatics 37 (2), 144–154 (1996) .
   Google Scholar
• Watson M, Wheatley K, Harrison GA et al. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MPG AML 10 trial. Cancer 86(7), 1231–1239 (1999).
   Google Scholar
• Cust MP, Whitehead MI, Powles R, Hunter M, Milliken S. Consequences and treatment of ovarian failure after total body irradiation for leukaemia. BE Med. J. 299(6714), 1494–1497 (1989).
   Google Scholar
• Landier W Childhood acute lymphoblastic leukemia: current perspectives. 017C01. NUTS. Forum 28 (5), 823–833 (2001) .
   Google Scholar
• Eiser C, Jenney ME. Measuring symptomatic benefit and quality of life in paediatric oncology. BE J. Cancer 73(11), 1313–1316 (1996).
   Google Scholar
• Rao GP, Malhotra S, Marwaha RK. Psychosocial study of leukemic children and their parents. Indian Pecliatc 29(8), 985–990 (1992).
   Google Scholar
• Stuber ML, Christakis DA, Houskamp B, Kazak AE. Post-trauma symptoms in childhood leukemia survivors and their parents. Fiychosomatics 37(3), 254–261 (1996).
   PubMed Web of Science ®Google Scholar
• Tarr J, Piclder RII. Becoming a cancer patient: a study of families of children with acute lymphocytic leukemia. J. Pecliatc Onto. Nuts. 16(1), 44–50 (1999).
   Google Scholar
• Kazak AE, Penati B, Boyer BA et al A randomized controlled prospective outcome study of a psychological and pharmacological intervention protocol for procedural distress in pediatric leukemia. Pecliatc Fiychol. 21(5), 615–631 (1996).
   Google Scholar
• Kornblith AB, Herndon JE, Zuckerman E et al Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann. Onto. 9(3), 297–306 (1998).
   Google Scholar
• Neglia JR Late effects of treatment in children with cancer. Semin. Pecliatc Surg. 2(1), 29–36 (1993).
   Google Scholar
• Waber DP, Shapiro BL, Carpentieri SC et al Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87–01. Cancer92(1), 15–22 (2001).
   Google Scholar
• Anderson V, Smibert E, Ekert H, Godber T Intellectual, educational and behavioural sequelae after cranial irradiation and chemotherapy. Arch. Dis. Child. 70(6), 476–483 (1994).
   Google Scholar
• Warner JT, Evans WD, Webb DK, Gregory JW. Body composition of long-term survivors of acute lymphoblastic leukaemia. Med Pediatr. Onto. 38(3), 165–172 (2002).
   Google Scholar
• Brown RT, Sawyer MG, Antoniou G, Toogood I, Rice M. Longitudinal follow-up of the intellectual and academic functioning of children receiving central nervous system-prophylactic chemotherapy for leukemia: a four-year final report. J. Dev. Behav. Pecliatr. 20(5), 373–377 (1999).
   Google Scholar
• Espy KA, Moore IM, Kaufmann PM, Kramer JH, Matthay K, Hutter JJ. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. J. Peclian: Psycho. 26(1), 1–9 (2001).
   Google Scholar
• Moe PJ, Holen A. High-dose methotrexate in childhood ALL. Pecliatc Hematol Onto. 17(8), 615–622 (2000).
   Google Scholar
• Black P, Gutjahr P, Stopfkuchen H. Physical performance in long-term survivors of acute leukaemia in childhood. Fur. J. Pecliatr. 157(6), 464–467 (1998).
   Google Scholar
• Lonnerholm G, Simonsson B, Arvidson J et al Autologous bone marrow transplantation in children with acute lymphoblastic leukemia. Acta. Paecliatc 81(12), 1017–1022 (1992).
   Google Scholar
• Hays K, McCartney S. Nursing care of the patient with chronic lymphocytic leukemia. Semin. Onto. 25(1), 75–79 (1998).
   Google Scholar
• Osterborg A, Brandberg Y, Molostova V et al Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetizn beta, in hematologic malignancies.' Clin. Oncol 20(10), 2486–2494 (2002).
   Google Scholar
• Siakantaris MP, Angelopoulou MK, Vassilakopoulos TP, Dimopoulou MN, Kontopidou FN, Pangalis GA. Correction of disease-related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain response. Leuk. Lymphoma 40(1-2), 141–147 (2000).
   PubMed Web of Science ®Google Scholar
• Haber J, Spicka I, Petruzelka L et al Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases — chronic lymphadenosis and multiple myeloma. Vnitc Lek. 42(4), 262–267 (1996).
   Google Scholar
• Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeloid leukemiain Sweden. Int. J. Technol Assess. Healthcare 10(4), 683–694 (1994).
   Google Scholar
• •The only comprehensive burden estimate for any leukemia that includes indirect costs.
   Google Scholar
• Schuette HL, Tucker TC, Brown ML, Potosky AL, Samuel T The costs of cancer care in the United States: implications for action. Oncology ffluntingt)9\(Suppl. 11), 19–22 (1995).
   Google Scholar
• Brown ML, Fintor L. The economic burden of cancer. In: Cancer Prevention and Control. Greenwald P (Ed.). Marcel-Dekker Publishers, NY, USA, 69–81 (1995).
   Google Scholar
• Baker MS, Kessler LG, Smucker RC. Site-specific treatment costs for cancer: an analysis of the medicare continuous history sample file. In: Cancer Cate and Costs. Scheffler RM, Andrews NC (Eds). Health Administration Press, Ann Arbor, MI, USA, 127–138 (1989).
   Google Scholar
• Agency for Healthcare Research and Quality (AHRQ). HCUPnet, Healthcare Cost and Utilization Project (2002).
   Google Scholar
• Brown ML, Hodgson TA, Rice DP Economic impact of cancer in the United States. In: Cancer Epidemiology and ffevention. Schottenfeld D (Ed.). Oxford University Press, NY, USA, 255–266 (1996).
   Google Scholar
• Stommel M, Kingry M. Support patterns for spouse-caregivers of cancer patients. The effect of the presence of minor children. Cancer Nuts. 14(4), 200–205 (1991).
   Google Scholar
• Houts PS, Lipton A, Harvey HA et al. Nonmedical costs to patients and their families associated with out-patient chemotherapy. Cancer 53 (11), 2399–2392 (1984).
   Google Scholar
• Lansky SB, Cairns NU, Clark GM et al. Childhood cancer: nonmedical costs of the illness. Cancer 43(1), 403–408 (1979).
   Google Scholar
• Lansky SB, Black JL, Cairns NU. Childhood cancer. Medical costs. Cancer 52(4), 762–766 (1983).
   Google Scholar
• Bloom BS, Knorr RS, Evans AE. The epidemiology of disease expenses. The costs of caring for children with cancer. JAMA 253(16), 2393–2397 (1985).
   Google Scholar
• Close P, Burkey E, Kazak A, Danz P, Lange B. A prospective, controlled evaluation of home chemotherapy for children with cancer. Pediatrics 95(6), 896–900 (1995).
   PubMed Web of Science ®Google Scholar
• Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch. Intern. Med. 162(14), 1597–1603 (2002).
   Google Scholar
• •Most recent economic analysis of any type of leukemia using US Medicare data.
   Google Scholar
• Stalfelt AM, Brodin H. Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades. J. Intern. Med. 236(4), 401–409 (1994).
   Google Scholar
• Rahiala J, Riikonen P, Kekalainen L, Perkkio M. Cost analysis of the treatment of acute childhood lymphocytic leukaemia according to Nordic protocols. Acta Paediatr. 89 (4), 482–487 (2000) .
   Google Scholar
• Kurre HA, Ettinger AG, Veenstra DL et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coliL-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). j Pediatr. Hematol Oncol 24(3), 175–181 (2002).
   Google Scholar
• •One of the few formal economic analyses of drug therapy in childhood leukemia.
   Google Scholar
• Gaynon PS, Bostrom BC, Hutchinson RJ et al Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies.j Clin. Oncol 19 (7), 1916–1925 (2001).
   Google Scholar
• Horowitz HW, Holmgren D, Seiter K. Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leuk. Lymphoma 23 (1–2), 159–163 (1996). iii Sajben P, Minarik T, Tomasik E et al Fluconazol plus ofloxacin in prophylaxis of infections in patients with acute leukemia: a comparative study. Support Cate Cancer 1(4), 214–216 (1993).
   Google Scholar
• Buda K, Tubergen DG, Levin MJ. The frequency and consequences of varicella exposure and varicella infection in children receiving maintenance therapy for acute lymphoblastic leukemia. Pediatr. Hematol Oncol 18(2), 106–112 (1996).
   Google Scholar
• Pui CH, Boyett JM, Hughes WT et al Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl. J. Med. 336 (25), 1781–1787 (1997).
   Google Scholar
• Mitchell PL, Morland B, Stevens MC et al Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Clin. Oncol 15(3), 1163–1170 (1997).
   Google Scholar
• BR, Singer JW, Weschler JM et al Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial. Pharmacoeconomics 6(1), 42–48 (1994).
   Google Scholar
• Little MA, Morland B, Chisholm J et al A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med. Pecliatr Oncol 38(2), 98–103 (2002).
   PubMedGoogle Scholar
• Bennett CL, Stinson TJ, Laver JH, Bishop MR, Godwin JE, Tallman MS. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making? Leuk. Lymphoma 37 (1-2), 65–70 (2000).
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pession A, Zecca M et al Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia. Bone Marrow 71ansplant.17 (1), 31–37 (1996).
   Google Scholar
• Holdsworth MT, Duncan MH. Healthcare outcomes case study: Febrile neutropenia. Ainj Health Syst. Pharm. 52(19 Suppl. 4), S15—S18 (1995).
   Google Scholar
• Saarinen-Pihkala UM, Lanning M, Perkkio M et al Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Med. Perliatr Oncol 34(5), 319–327 (2000).
   Google Scholar
• Bennett CL, Stinson TJ, Lane D, Amylon M, Land VJ, Laver JH. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in co-operative group trials. Med. Pecliatr Oncol 34(2), 92–96 (2000).
   PubMedGoogle Scholar
• Bassan R, Lerede T, Di Bona E et al Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics and costs. Leuk. Lymphoma 26(1-2), 153–161 (1997).
   PubMed Web of Science ®Google Scholar
• Barr R, Furlong W, Henwood J et al Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J. Clin. Oncol 14(5), 1413–1420 (1996).
   Google Scholar
• Durand-Zaleski I. Fixed price contracts: the case of pediatric acute lymphoblastic leukemia. Health Policy 21 (1), 65–76 (1992).
   Google Scholar
• Yalman N, Sarper N, Devecioglu 0 et al Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk Pediatr 42(3), 198–204 (2000).
   Google Scholar
• Cobbs LS, Clark PA, Brusa M. The million dollar question. Hastings Cent. Rep. 30(5), 24–26 (2000).
   Google Scholar
• Kattan MW, Inoue Y, Giles FJ et al. Cost-effectiveness of interferon-a and conventional chemotherapy in chronic myelogenous leukemia. Ann. Intern Merl 125(7), 541–548 (1996).
   Google Scholar
• Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon-a in chronic myelogenous leukemia. J. Clin. Oncol 15(7), 2673–2682 (1997).
   Google Scholar
• Messori A. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. Ann. Oncol 9(4), 389–396 (1998).
   Web of Science ®Google Scholar
• Beck JR, Guilhot J, Giles FJ, Aoki N, Wirt DP, Guilhot E Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia. Leuk. Lymphoma 41(1-2), 117–124 (2001).
   PubMed Web of Science ®Google Scholar
• Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood 92(11), 4047–4052 (1998).
   PubMed Web of Science ®Google Scholar
• Mishra V, Vaaler S, Brinch L. A prospective cost evaluation related to allogeneic haemopoietic stem cell transplantation including pretransplant procedures, transplantation and 1-year follow-up procedures. Bone Marrow 71amplant. 28(12), 1111–1116 (2001).
   Google Scholar
• Griffiths RI, Bass EB, Powe NR, Anderson GF, Goodman S, Wingard JR. Factors influencing third party payer costs for allogeneic BMT. Bone Marrow 71amplant.12(1), 43–48 (1993).
   Google Scholar
• Hyde C, Wake B, Bryan S et al. Fludarabine as second-line therapy for B-cell chronic lymphocytic leukaemia: a technology assessment. Health Technol Assess. 6(2), 1–89 (2002).
   Google Scholar
• Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl. J. Merl 325(2), 81–86 (1991).
   Google Scholar
• Mason JM, Drummond MF, Bosanquet AG, Sheldon TA. The DiSC assay. A cost-effective guide to treatment for chronic lymphocytic leukemia? Int. J. 7chnol. Assess. Healthcare 15 (1), 173–184 (1999).
   Google Scholar
• Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. Clin. °Tirol 18(1), 64–71 (2000).
   PubMed Web of Science ®Google Scholar
• •Comprehensive analysis comparing autologous with allogeneic transplants and their complications.
   Google Scholar
• Bennett C, Waters T, Stinson T et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone MarIVW Transplant. 24(5), 555–560 (1999).
   Google Scholar
• Viens-Bitker C, Fery-Lemonnier E, Blum-Boisgard C et al Cost of allogeneic bone marrow transplantation in four diseases. Health Policy12(3), 309–317 (1989).
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot CA, Gelderblom-den Hartog J, Huijgens PC, Willemze R, van Ineveld BM. Costs of diagnosis, treatment and follow-up of patients with acute myeloid leukemia in The Netherlands. J. Hematother. Stem Cell Res. 10(1), 187–192 (2001).
   Google Scholar
• Dufoir T, Saux MC, Terraza B et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow 71amplant. 10(4), 323–329 (1992).
   Google Scholar
• Welch HG, Larson EB. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl. J. Merl 321(12), 807–812 (1989).
   Google Scholar
• Madero L, Gonzalez VM, Ramirez M, Quintero V, Benito A, Diaz MA. Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone MarIVW Transplant. 26(3), 269–273 (2000).
   Google Scholar
• Blaise D, Kuentz M, Fortanier C et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. j Gun. Oncol 18(3), 537–546 (2000).
   Google Scholar
• Faucher C, Fortanier C, Viens P et al. Clinical and economic comparison of lenograstim-primed blood cells (BC) and bone marrow (BM) allogeneic transplantation. Bone Marrow Transplant. 21 (Suppl. 3) S92—S98 (1998).
   Google Scholar
• IARC Scientific Publications. Cancer Incidence in Five Continents. IARC Scientific Publications, No. 143, Lyon, France (1997).
   Google Scholar
• Aquino VM. Acute myelogenous leukemia. Curr. Probl Perliatc Adolesc. Healthcam 32(2), 50–58 (2002).
   Google Scholar
• Smith S, Beltz S. Acute leukemias. In: Pharmacotherapy: a Pathophysiologic Approach. Dipiro JT, Talbert R, Yee G, Matzke G, Wells B, Posey L (Eds). McGraw-Hill, NY, USA, 2149–2168 (1999).
   Google Scholar
• Pogoda JM, Preston-Martin S, Nichols PW, Ross RK. Smoking and risk of acute myeloid leukemia: results from a Los Angeles County case-control study. Am. J. Epidemiol 155(6), 546–553 (2002).
   Google Scholar
• Sandler DP, Ross JA. Epidemiology of acute leukemia in children and adults. Sernin. Oncol 24(1), 3–16 (1997).
   Google Scholar
• Lee SJ. Chronic myelogenous leukaemia. Br. Haematol 111(4), 993–1009 (2000).
   Google Scholar
• McGuire TR, Kazakoff PW. In: Pharmacotherazpy: a Pathophysiologic Approach. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey, LM (Eds). Elservier, NY, USA (1999).
   Google Scholar
• Yuille MR, Matutes E, Marossy A, Hilditch B, Catovsky D, Houlston RS. Familial chronic lymphocytic leukaemia: a survey and review of published studies. BE I Haematol 109(4), 794–799 (2000).
   PubMed Web of Science ®Google Scholar
• Cancer Statistics: Cancer Facts and Figums 2002. American Cancer Society, Atlanta, GA, USA, (2002).
   Google Scholar
• Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl. J. Med. 341(3), 164–172 (1999).
   Google Scholar
• Molassiotis A, Boughton BJ, Burgoyne T, van den Akker OB. Comparison of the overall quality of life in 50 long-term survivors of autologous and allogeneic bone marrow transplantation. J. Adv. NUTS. 22(3), 509–516 (1995).
   Google Scholar
• Matthes-Martin S, Lamche M, Ladenstein R et al. Organ toxicity and quality of life after allogeneic bone marrow transplantation in pediatric patients: a single center retrospective analysis. Bone Mal-IOW Barb-134117r. 23(10), 1049–1053 (1999).
   Google Scholar
• Sarafoglou K, Boulad F, Gillio A, Sklar C. Gonadal function after bone marrow transplantation for acute leukemia during childhood. J. &Ilan: 130(2), 210–216 (1997).
   Google Scholar
• Mottonen M, Uhari M. Social activities in the families of children with acute lymphoblastic leukemia. Perliatc Hematol Oncol 12(4), 371–375 (1995).
   Web of Science ®Google Scholar
• Faucher C, Fortanier C, Le Corroller AG et al Clinical economic and quality of life assessment of lenograstim priming and peripheral blood progenitor cells (PBSC) harvesting for 31 healthy donors. Bone Marmw 71ansplant. 21\(Suppl. 1), S40 (1998).
   Google Scholar
• Ollenschlager G, Thomas W Konkol K, Diehl V, Roth E. Nutritional behaviour and quality of life during oncological polychemotherapy: results of a prospective study on the efficacy of oral nutrition therapy in patients with acute leukaemia. Furj Gun. Invest 22(8), 546–553 (1992).
   Google Scholar
• Moe PJ, Holen A, Glomstein A et al. Long-term survival and quality of life in patients treated with a national ALL protocol 15–20 years earlier: IDM/HDM and late effects? Perliatr Hematol Oncol 14(6), 513–524 (1997).
   Google Scholar
• Barr RD, Gonzalez A, Longchong M et al. Health status and health-related quality of life in survivors of cancer in childhood in Latin America: a MISPHO feasibility study. Int.j Oncol 19 (2), 413–421 (2001).
   Google Scholar
• Kazak AE, Barakat LP, Meeske K et al. Post-traumatic stress, family functioning and social support in survivors of childhood leukemia and their mothers and fathers. .1. Consult. Clin. Pwchol. 65(1), 120–129 (1999).
   Google Scholar
• Kazak AE, Barakat LP Brief report: parenting stress and quality of life during treatment for childhood leukemia predicts child and parent adjustment after treatment ends. J. Pediatr Pwchol. 22(5), 749–758 (1997).
   PubMed Web of Science ®Google Scholar
• Sharan P, Mehta M, Chaudhry VP. Coping and adaptation in acute lymphoblastic leukemia. Indianj Perliatr 62(4), 467–471 (1995).
   Google Scholar
• Evans DR, Thompson AB, Browne GB, Barr RN/I, Barton WB. Factors associated with the psychological well-being of adults with acute leukemia in remission. J. Clin. Pwchol. 49(2), 153–160 (1993).
   Google Scholar
• Balduzzi A, Gooley T, Anasetti C et al Unrelated donor marrow transplantation in children. B/ooc/86(8), 3247–3256 (1995).
   Google Scholar
• Molassiotis A, Morris PJ. Quality of life in patients with chronic myeloid leukemia after unrelated donor bone marrow transplantation. Cancer Nuts. 22 (5), 340–349 (1999).
   Google Scholar
• Kiss 11, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. Clin. Oncol 20(9), 2334–2343 (2002).
   Google Scholar
• •Most recent long-term follow-up of quality of life outcomes in chronic myeloid leukemia after bone marrow transplant
   Google Scholar
• Bush NE, Haberman M, Donaldson G, Sullivan KM. Quality of life of 125 adults surviving 6–18 years after bone marrow transplantation. Soc. ScL Med. 40(4), 479–490 (1995).
   Google Scholar
• Broers S, Kaptein AA, Le Cessie S, Fibbe W, Hengeveld MW. Psychological functioning and quality of life following bone marrow transplantation: a 3-year follow-up study. I Pwchosom. Res. 48(1), 11–21 (2000).
   Google Scholar
• Andrykowski MA, Greiner CB, Altmaier EM et al. Quality of life following bone marrow transplantation: findings from a multicenter study. BE J. Cancer 71(6), 1322–1329 (1995).
   Google Scholar
• Belec RII. Quality of life: perceptions of long-term survivors of bone marrow transplantation. Oncol NUTS. Forum 19(1), 31–37 (1992).
   Google Scholar
• Andrykowski MA, Altmaier EM, Barnett RL, Otis ML, Gingrich R, Henslee-Downey PJ. The quality of life in adult survivors of allogeneic bone marrow transplantation. Correlates and comparison with matched renal transplant recipients. Transplantation 50(3), 399–406 (1990).
   Google Scholar
• Andrykowski MA, Bruehl S, Brady MJ, Henslee-Downey PJ. Physical and psychosocial status of adults one-year after bone marrow transplantation: a prospective study. Bone Marrow 7iansplant. 15(6), 837–844 (1995).
   Google Scholar
• Andrykowski MA, Altmaier EM, Barnett RL, Burish TG, Gingrich R, Henslee-Downey PJ. Cognitive dysfunction in adult survivors of allogeneic marrow transplantation: relationship to dose of total body irradiation. Bone Marrow Transplant. 6(4), 269–276 (1990).
   Google Scholar
• Parth P, Dunlap WP, Kennedy RS, Ordy JM, Lane NE. Motor and cognitive testing of bone marrow transplant patients after chemoradiotherapy. Percept. Mot. Skills 68(3Pt 2), 1227–1241 (1989).
   Google Scholar
• Andrykowski MA, Brady MJ, Henslee-Downey PJ. Psychosocial factors predictive of survival after allogeneic bone marrow transplantation for leukemia. Psychosom. Med. 56(5), 432–439 (1994).
   Google Scholar
• Andrykowski MA, Cordova MJ, Hann DM, Jacobsen PB, Fields KK, Phillips G. Patients' psychosocial concerns following stem cell transplantation. Bone Marrow Transplant. 24(10), 1121–1129 (1999).
   Google Scholar
• Hjermstad MJ, Evensen SA, Kvaloy SO, Fayers PM, Kaasa S. Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: a prospective study.j Clin. Oncoll7 (2), 706–718 (1999).
   Google Scholar
• Waber DR More good news about neuropsychological late effects in long-term survivors of acute lymphoblastic leukemia. Perliatr Hematol Oncol 24(2), 86–87 (2002).
   Google Scholar
• Baker F, Wingard JR, Curbow B et al Quality of life of bone marrow transplant long-term survivors. Bone MarMW Barb-134317r. 13(5), 589–596 (1994).
   Google Scholar
• Molassiotis A, van den Akker OB, Milligan DW et al. Quality of life in long-term survivors of marrow transplantation: comparison with a matched group receiving maintenance chemotherapy. Bone Marrow Transplant. 17(2), 249–258 (1996).
   Google Scholar
• Bertero C, Eriksson BE, Ek AC. A substantive theory of quality of life of adults with chronic leukaemia. Int. J. Nuts. Stud. 34(1), 9–16 (1997).
   Google Scholar
• Levy V, Porcher R, Delabarre F, Leporrier M, Cazin B, Chevret S. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. Clin. Epidemiol 54(7), 747–754 (2001).
   PubMed Web of Science ®Google Scholar
• Holzner B, Kemmler G, Spemer-Unterweger B et al. Quality of life measurement in oncology: a matter of the assessment instrument? Eur j Cancer 37(18), 2349–2356 (2001).
   Google Scholar
• Craft AW. Childhood cancer-mainly curable so where next? Acta Paecliatr 89(4), 386–392 (2000).
   Google Scholar
• Stalfelt AM, Brodin H, Wadman B. Cost analysis of different phases of acute myeloid leukaemia. Leuk. Res. 18(10), 783–790 (1994).
   Google Scholar
• Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A et al. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands. Bone Marrow Transplant. 15(4), 605–610 (1995).
   Google Scholar
• Clavio M, Quintino S, Masoudi B et al Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. .1. Exp. Clin. Cancer Res. 20(2), 165–173 (2001).
   Google Scholar
• Marie JP, Wdowik T, Bisserbe S, Zittoun R. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug. Leukemia 6(7), 720–722 (1992).
   PubMed Web of Science ®Google Scholar
• Lobo PJ, Powles RL, Hanrahan A, Reynold DK. Acute myeloblastic leukaemia: a model for assessing value for money for new treatment programmes. BE Med J. 302(6772), 323–326 (1991).
   Google Scholar
• Pashko S, Jacobs J, Santorsa J. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia. Clin. Ther 13 (3), 353–360 (1991).
   Google Scholar
• Bennett CL, Stinson TJ, Tallman MS et al Economic analysis of a randomized placebo-controlled Phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia. Eastern Co-operative Oncology Group (E1490). Ann. Oncoll0(2), 177–182 (1999).
   Google Scholar
• Wagner ND, Quinones VW Allogeneic peripheral blood stem cell transplantation: clinical overview and nursing implications. Oncol NUTS. Forum 25 (6), 1049–1055 (1998).
   Google Scholar
• Bennett CL, Bishop MR, Tallman MS, Somerfield MR, Feinglass J, Smith TJ. The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology. Ann. 0=1 10(11), 1355–1359 (1999).
   Google Scholar
• Allan DS, Buckstein R, Imrie KR. Out-patient supportive care following chemotherapy for acute myeloblastic leukemia. Leuk. Lymphoma 42 (3), 339–346 (2001).
   Google Scholar
• Girmenia C, Alimena G, Latagliata R et al Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. Thematologica 84(9), 814–819 (1999).
   Google Scholar
• Beard ME, Inder AB, Allen JR, Hart DN, Heaton DC, Spearing RL. The costs and benefits of bone marrow transplantation. NZ Med 104(916), 303–305 (1991).
   Google Scholar
• Chandy M. Childhood acute lymphoblastic leukemia in India: an approach to management in a three-tier society. Med. Pediatr. Oncol 25 (3), 197–203 (1995).
   Google Scholar
• Ribeiro RC, Bonilla M. A leukaemia treatment programme in El Salvador. Lancet 356 (Suppl.), S7 (2000) .
   Google Scholar
• von Stackelberg A, Karatchunsky A, Kudrjashova J et al Toxicity, supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90m and MB 91. Eur. Cancer 35(9), 1349–1355 (1999).
   Google Scholar
• Bleyer A. CNS chemoradiotherapy of childhood leukemia: the plot thickens but the ending bodes well. j Gun. Oncol 13(10), 2480–2482 (1995).
   Google Scholar
• Ettinger U. Asparaginases: where do we go from here?" Perliatr Hematol Oiled 21(1), 3–5 (1999).
   Google Scholar
• Holle LM. Pegaspargase: an alternative? Ann. Phatmacother. 31(5), 616–624 (1997).
   Google Scholar
• Peters BG, Goeckner BJ, Ponzillo JJ, Velasquez WS, Wilson AL. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Formulary 30(7), 388–393 (1995).
   Google Scholar
• Sullivan MJ, Abbott GD, Robinson BA. Ondansetron anti-emetic therapy for chemotherapy and radiotherapy induced vomiting in children. NZ Med. J. 105(942), 369–371 (1992).
   Google Scholar
• Baranko PV. A cost comparison of laboratory charges in treating childhood leukemia. A children's cancer group analysis. Am. .1. Perliatr Hematol Oncol 16(2), 102–103 (1994).
   Google Scholar
• Veenstra DL, Higashi MK, Phillips IKA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2(3), E29 (2000).
   PubMedGoogle Scholar
• Tonnaire G, Gabert J, Lafage-Pochitaloff M et al Cytogenetic and molecular biology for acute leukemias at diagnosis: a cost/effectiveness comparison. Leuk Lymphoma 28(3-4), 363–370 (1998).
   PubMed Web of Science ®Google Scholar
• Goulden N, Oakhill A, Steward C. Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia annotation. BE j Haematol 112(2), 275–281 (2001).
   Google Scholar
• Poteat HT, Sklar J. A simplified polymerase chain reaction assay for detection of chromosomal translocations in hematologic malignancies. Diagn. Mal Pathol 6(1), 3–9 (1997).
   Google Scholar
• Baltz JK, Montello MJ. Cladribine for the treatment of hematologic malignancies. Clin. Phalli?. 12(11), 805–813 (1993).
   PubMedGoogle Scholar
• Marchetti M, Barosi G, Liberato LN. Fludarabine for chronic lymphocytic leukemia. N Engif Med. 344(15), 1166–1167 (2001).
   PubMedGoogle Scholar
• Bosanquet AG, Johnson SA, Richards SM. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. BE j Haematol 106(1), 71–77 (1999).
   PubMedGoogle Scholar
• Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J. Am. Phatm. Assoc. NO 42 (3), 449–458 (2002) .
   Google Scholar
• Timmerman PR. Intravenous immunoglobulin in oncology nursing practice. Oncol NUTS. Forum20(1), 69–75 (1993).
   Google Scholar
• Venuta F, Rendina EA, Pescarmona EO et al Ambulatory mediastinal biopsy for hematologic malignancies. Eur. Catrliothorac. Surg. 11(2), 218–221 (1997).
   Google Scholar